Details

Autor(en) / Beteiligte

• Rees, Gwen S.
• Trikic, Michael Z.
• Winther, Jeanette F.
• Tawn, E Janet
• Stovall, Marilyn
• Olsen, Jørgen H.
• Rechnitzer, Catherine
• Schrøder, Henrik
• Guldberg, Per
• Boice, John D.

Titel

A pilot study examining germline minisatellite mutations in the offspring of Danish childhood and adolescent cancer survivors treated with radiotherapy

Ist Teil von

• International journal of radiation biology, 2006-03, Vol.82 (3), p.153-160

Ort / Verlag

England: Informa UK Ltd

Erscheinungsjahr

2006

Quelle

Taylor & Francis Journals Auto-Holdings Collection

Beschreibungen/Notizen

• Purpose:To investigate germline mutation rate at eight minisatellite loci in 24 Danish families, where one parent is the survivor of childhood or adolescent cancer treated with radiotherapy. Materials and methods:Parents and offspring were profiled for eight hypervariable minisatellite loci (B6.7, CEB1, CEB15, CEB25, CEB36, MS1, MS31, MS32) by Southern blotting. Results:Seven paternal mutations were observed for 130 informative alleles in 18 offspring from 11 radiation-exposed fathers (mean preconceptional dose for offspring 0.29 Gy, range <0.01 - 1.2 Gy), compared to six mutations for 146 informative alleles in 21 offspring from 13 unexposed fathers. No statistically significant difference between the total paternal mutation rates was observed (5.4% for exposed fathers and 4.1% for unexposed fathers). Three maternal mutations were observed for 148 informative alleles in 21 offspring from 13 radiation-exposed mothers (mean preconceptional dose for offspring 0.71 Gy, range <0.01 - 9.2 Gy), compared to one mutation for 130 informative alleles in 18 offspring from 11 unexposed mothers. Again, no statistically significant difference was observed between the total maternal mutation rates (2.0% for exposed mothers and 0.8% for unexposed mothers). Conclusions:The data from this pilot study demonstrate no statistically significant increase in germline minisatellite mutation rate associated with radiotherapy for childhood and adolescent cancer.